Nanjing Medical University

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Retrieved on: 
Friday, April 5, 2024
IOV, Tao, Medicine, Savolitinib, VEGFR, Immunotherapy, Patient, MMAE, ERK, Relapse, Neoplasm, University, Huachung University, Cisplatin, Lymphoid leukemia, Lymphoma, Chongqing Medical University, Cholangiocarcinoma, Tyrosine-protein kinase SYK, Classification, Efficacy, MET, ADC, Cardiotoxicity, Nanjing Medical University, Non-receptor tyrosine kinase, Safety, Ferroptosis, Macrophage, Pancreatic cancer, Dual role, National Taiwan University Hospital, GPR34, Oncology, Guangzhou Medical University, MD Anderson Cancer Center, Daratumumab, HCM, NPM1, MLL, 301 Hospital, Acute leukemia, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
  • Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia.
  • Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models.
  • Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo.

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Congress, Capecitabine, Sintilimab, Nanjing Medical University, HKEX, The First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Xinjiang Medical University, European Society for Medical Oncology, Oncology, Fudan University, Maintenance, Shanghai Cancer Center, Radiation, Patient

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.
  • Details of the presentations are as follows:
    Fruquintinib plus Sintilimab in patients with either treatment naïve or previously treated advanced gastric or gastroesophageal junction adenocarcinoma: results from a multicenter, single-arm phase Ib/II study
    Xiaoli Wei, Harbin Medical University Cancer Hospital, Harbin, China
    First report of the safety/tolerability and preliminary antitumor activity of fruquintinib plus capecitabine versus capecitabine as maintenance treatment for metastatic colorectal cancer: an open-label, randomized phase Ib/II study
    Wenhua Li, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
    Fuxiang Zhou, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
    Lu Wang, Liver surgery department, Fudan University Shanghai Cancer Center, Shanghai, China
    Pei Ma, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology

Retrieved on: 
Tuesday, February 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, American Journal of Hematology, CR, Journal, CLL, OS, TP53, Nanjing Medical University, Aes, Patient, IGHV, SCI, SCIE, The First Affiliated Hospital of Wenzhou Medical University, American Journal, First Affiliated Hospital of Xinjiang Medical University, Malignancy, Lymphocytosis, ORR, Progression-free survival, SLL, Chronic lymphocytic leukemia, Observation, BTK, PFS, Leukemia, Death, Pharmaceutical industry, Relapse, Hematology

American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.

Key Points: 
  • American Journal of Hematology recently published the phase 2 study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) patients.
  • The journal concluded that monotherapy of orelabrutinib demonstrated compelling efficacy and a well-tolerated safety profile, with a significant number of patients achieving CR in R/R CLL/SLL.
  • The American Journal of Hematology is an academic journal focusing on hematology, which was founded in 1976 and published monthly by WILEY publisher.
  • Note: In addition to background information, the content of this press release is derived from this published article.

Geneseeq Publishes Promising Early Lung Cancer Detection Results in AJRCCM

Retrieved on: 
Tuesday, November 15, 2022
American Journal of Respiratory and Critical Care Medicine, Circulating tumor DNA, DECIPHER, Plasma, Survival, Clinical Laboratory, Nanjing Medical University, EDM, Squamous cell carcinoma, Neoplasm, AUC, CLIA, ISO, College of American Pathologists, Cancer, College, BPM, Adenocarcinoma, Trial of the century, Multimedia, FSC, FSD, Program, American Journal, Lung cancer, Patient, Nucleic acid thermodynamics, DNA, CNV, WGS, Critical Care Medicine (journal), Machine learning, Medical imaging, Pharmaceutical industry

TORONTO, Nov. 15, 2022 /PRNewswire/ - Geneseeq Technology Inc. ("Geneseeq"), a company focused on advancing cancer genomic profiling through cutting-edge next-generation based technologies, today announced high-performing results from a lung cancer study testing the company's early cancer detection model through program DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features).

Key Points: 
  • TORONTO, Nov. 15, 2022 /PRNewswire/ - Geneseeq Technology Inc. ("Geneseeq"), a company focused on advancing cancer genomic profiling through cutting-edge next-generation based technologies, today announced high-performing results from a lung cancer study testing the company's early cancer detection model through program DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features).
  • Geneseeq has extensively evaluated a multi-dimensional, early cancer detection model based on cfDNA fragmentomics and achieved consistent and excellent performance.In this study, Geneseeq and Jiangsu Cancer Hospital demonstrated the high predictability, stability, and robustness of this model in a early-stage lung cancer population, including patients with extremely low circulating tumor DNA (ctDNA) levels.
  • The remarkable performance of our early cancer detection model has given us confidence in its real-world and clinical application", says Dr. Hua Bao, author and the director of Geneseeq Research Institute.
  • With a series of DECIPHER early cancer detection studies published in high-impact journals, Geneseeq also announced the progress of a large-cohort, prospective, early cancer screening clinical study named "Jinling Cohort" at the Nanjing headquarters earlier this year.

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, General Health, Health, Master of Laws, Medicine, Johnson & Johnson, MD Anderson Cancer Center, Senior, Business development, Schering-Plough, Leadership, History of the University of Maryland, College Park, NK, Board, Director, Research, International law, Patient, GenScript Biotech, Nasdaq, Therapy, Company, Doctor of Philosophy, Nanjing Medical University, 19th Presidential Awards, Nanjing University, NASDAQ, Sino Biopharmaceutical Limited, Shenzhen Stock Exchange, Immunotherapy, Biochemistry, Goal, University, University of Antwerp, Time, Duke University, Chair, Capital Group Companies, Management, Pharmaceutical industry

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang Frank Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang Frank Zhang as Class II director of Legend Biotech, and Dr. Li Mao as Class III director of Legend Biotech.
  • Dr. Frank Zhang, one of the newly appointed directors, was elected Chairman of the Board of Directors.
  • Both the size and composition of the Board have been under evaluation for some time.
  • We look forward to her many future contributions as she remains a strong asset to our Board.

Nimbus Therapeutics Strengthens Clinical Development Leadership Team

Retrieved on: 
Wednesday, April 13, 2022
Health, Biotechnology, Protein, Perelman School of Medicine at the University of Pennsylvania, HPK1, Southern New Hampshire University, MBA, Pathology, Ironwood Pharmaceuticals, Rheumatology, Drug, Vertex Pharmaceuticals, Autoimmunity, Janssen Pharmaceuticals, Patient, Merck, TYK2, Regulatory affairs, Johnson & Johnson, Therapy, CSL Behring, Yale school, Bhaskar, Proteostasis, Harvard University, University, Assistant, Merck & Co., Senior, Alexion Pharmaceuticals, Nanjing Medical University, Head, Yale School of Medicine, Pharmaceutical industry, Dermatology, Nimbus

Nimbus also announced that Bhaskar Srivastava, M.D., Ph.D. has been promoted to Senior Vice President, Clinical Development.

Key Points: 
  • Nimbus also announced that Bhaskar Srivastava, M.D., Ph.D. has been promoted to Senior Vice President, Clinical Development.
  • Their breadth of experience in clinical and regulatory leadership will be an asset to our team as we continue to progress three active clinical trials for our novel inhibitors of TYK2 and HPK1, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus.
  • Since joining Nimbus he has helped to sharpen our clinical development strategy and to position Nimbus to expand our TYK2 franchise into clinical trials on additional autoimmune and inflammatory diseases.
  • Ms. Poirier, Nimbus Vice President, Clinical Operations, served most recently as Vice President of Clinical Operations for Entasis Therapeutics, where she was responsible for strategic and operational planning of all clinical trials.